Experts believe vaccinating children is key to achieving herd immunity

Follow us on Google News:
 Experts believe vaccinating children is key to achieving herd immunity

Source: siam.pukkato, Shutterstock

Summary

  • With the world getting millions of COVID-19 vaccines daily, experts believe that herd immunity can only be achieved if children start getting vaccinated.
  • Vaccine developers are conducting pediatric clinical trials to confirm the efficacy of the vaccines in children.
  • Recently, Pfizer joined the race and started clinical trials in children as young as six months.

Even as vaccines reach millions of people daily worldwide, experts view vaccination in children as a critical step in ensuring that we achieve herd immunity to defeat the pandemic.

The CDC highlighted that getting children vaccinated is vital to reach herd immunity and protecting the world against the virus. Although fewer kids, compared to adults, have been infected by SARS-CoV-2, they can still become sick and spread the coronavirus, CDC emphasised.

Apart from children’s health risks, there are concerns about how easily they can spread the virus.

Child Vaccinations for Herd Immunity

Herd immunity occurs when a larger population becomes immune to a virus through vaccination, and the virus has no one to infect.

Director of the National Institute of Allergy and Infectious Diseases, Mr Anthony Fauci, stated that we cannot reach herd immunity until children are vaccinated.

Source: © Iqoncept | Megapixl.com

Mr Fauci added-

Some media reports mention that Dr Fauci has estimated 70-85% of the population would need to be vaccinated or become immune to achieve herd immunity.

Must Read: Could Herd Immunity Help in Preventing COVID-19?

Pediatric clinical trials of COVID-19 vaccine

Vaccine developers have started clinical trials on adolescents as well as younger children to evaluate the safety and efficacy of COVID-19 vaccines for each age.

© Spukkato | Megapixl.com

  • In the US, recently, Pfizer-BioNTech joined Moderna to conduct pediatric clinical trials of their COVID-19 vaccines.
  • Johnson & Johnson (NYSE:JNJ) is planning to commence its pediatric studies.
  • Last month in the UK, AstraZeneca started a clinical trial for its COVID-19 vaccine among 6–17-year-old children.
  • In China, Sinovac announced that the Company had submitted initial data to Chinese medical regulators demonstrating its vaccine is safe in children and adolescents.

Moreover, Pfizer Inc (NYSE:PFE) and Moderna Inc (NYSE:MRNA) anticipate releasing their findings shortly for how the two shots of their vaccines performed in the 12 and older children.

ALSO READ: EU could block vaccine export amid a shortage of AstraZeneca’s COVID-19 shots

Pfizer-BioNTech pediatric study will test their vaccine in children as young as six months old. The Company updated that the first young children in the vaccine’s pediatric trial have got their initial shots.

Pfizer study aims to examine how the vaccine jabs should be given to young children, who are not considered the most vulnerable to COVID-19 but can be infected and spread the virus.

DO READ: 3 Stocks to evaluate to beat pandemic woes

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK